Rheumatology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 2010 Annual European Congress of Rheumatology (EULAR)

Targeted Cytokine Blocker Efficacy in Rheumatoid Arthritis Trials

Rome, Italy / June 16-19, 2010

Rome - The rapid expansion of biological drug classes that downregulate the inflammatory response is substantially broadening the therapeutic options in rheumatoid arthritis (RA). Following a proliferation of tumour necrosis factor (TNF)...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the First Systemic Sclerosis World Congress

Focus on Systemic Sclerosis Patients For Early Diagnosis and Treatment of Pulmonary Arterial Hypertension

Florence, Italy / February 11-13, 2010

INTRODUCTION Systemic sclerosis (SSc) is a multi-system connective tissue disease characterized by excessive fibrosis, inflammation and vasculopathy; it affects both the skin and internal organs. A devastating complication of SSc is...

PRIORITY PRESS - 73rd Annual Meeting of the American College of Rheumatology

New Diagnostic and Severity Criteria Broaden Spectrum of Fibromyalgia Management

Philadelphia, Pennsylvania / October 17-21, 2009

Philadelphia - Fibromyalgia (FM) is a chronic, debilitating condition characterized by pain, fatigue, functional impairment and sleep disturbances. Until now, physicians have had only one set of criteria by which to diagnose the disorder,...

PRIORITY PRESS - 73rd Annual Meeting of the American College of Rheumatology

Vasoprotection in Systemic Sclerosis: New Strategies for Raynaud’s Phenomenon

Philadelphia, Pennsylvania / October 17-21, 2009

Philadelphia - Systemic sclerosis presents a vascular phenotype and Raynaud’s phenomenon (RP) is its most common initial symptom. Strategies aimed at protecting the vasculature from vasospasm and vasculopathy have the potential to modify...

ABSTRACTS IN PERSPECTIVE - based on presentations from the 73rd Annual Meeting of the American College of Rheumatology

Treatment Effects and Considerations for IL-6 Inhibition in Rheumatoid Arthritis

Philadelphia, Pennsylvania / October 17-21, 2009

EDITORIAL OVERVIEW: Majed Khraishi, MB, BCh, FRCPC Medical Director (Rheumatology), Nexus Clinical Research, Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John’s, Newfoundland Disease-modifying...

PRIORITY PRESS - 73rd Annual Meeting of the American College of Rheumatology

Update on Interleukin-6 Antagonism in Rheumatoid Arthritis

Philadelphia, Pennsylvania / October 17-21, 2009

Philadelphia - Blocking inflammation via various inflammatory pathways with biologic therapy has dramatically improved outcomes for patients with rheumatoid arthritis. Results from a clinical trials program on the novel interleukin-6 (IL-6)...

MEDICAL OPTIONS - Pain Management

Putting Risk in Perspective: Selective and Non-selective NSAIDs - Reviews from published literature

September 2009

SELECTING NSAIDs IN OSTEOARTHRITIS: A PRACTICAL APPROACH Editorial Review: Algis V. Jovaisas, MD, FRCPC Assistant Professor of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, Ontario Many factors conspire to emphasize the...

PRIORITY PRESS - 10th Annual European Congress of Rheumatology (EULAR)

Achieving and Maintaining Remission in RA: Long-term Data on IL-6 Inhibition

Copenhagen, Denmark / June 10-13, 2009

Copenhagen - In the management of rheumatoid arthritis (RA), achieving and maintaining clinical remission and attenuating the risk of increasing disability are among the most important treatment goals. With sustained clinical remission,...

ABSTRACTS in PERSPECTIVE based on presentations from the 10th Annual European Congress of Rheumatology (EULAR)

Inflammation Control in Rheumatoid Arthritis Through Interleukin-6 Inhibition

Copenhagen, Denmark / June 10-13, 2009

EDITORIAL OVERVIEW: Alfred A. Cividino, MD, FRCPC, Clinical Professor of Medicine, Division of Rheumatology, McMaster University, Hamilton, Ontario If inflammation over time equals joint damage, then timely control of rheumatoid arthritis...

PRIORITY PRESS - British Society for Rheumatology and British Health Professionals in Rheumatology Annual Conference

IL-6 Receptor Inhibition in Rheumatoid Arthritis: New Insights from Clinical Trials

Glasgow, UK / April 28-May 1, 2009

Glasgow - Between 30% and 40% of patients with rheumatoid arthritis (RA) fail to respond to currently available disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents, creating a need for new agents that target novel...

PAGE 4 OF 7   1 2 3 4 5 6 7